Evolving concepts in the management of male LUTS/BPH

Industry session by RECORDATI SPA

  • Location:
    Room London (Hall B2, level 0)
  • Chair:
     C.G. Roehrborn, Dallas (US)
  • Aims and objectives of this session

    Focusing on alpha-blocker therapy, experts’ views of approaches for diagnosing and treating men with lower urinary tract symptoms (LUTS) due to BPH will be presented, along with pathophysiological insights into functional mechanism emerging from urodynamic investigations.
    Special focus will be set on patient reported outcomes, investigating the relevance of a bladder diary in both baseline assessment and during follow up and monitoring of treatment effects. The value of bladder diaries in comparison with other evaluating questionnaires will be discussed.
    Emerging evidence on the latest theories about the treatment-associated improvement of LUTS and urodynamic findings will be discussed, exploring the potential effects of alpha-blockers on bladder outlet obstruction.
    The unique role of alpha blockers as a foundation drug in the treatment for most men with mLUTS/BPH will be presented as a concept with supporting evidence.
    Cases discussed in the final round table will serve to reinforce the main teaching points and allow for audience participation.

 C.G. Roehrborn, Dallas (US)
The evaluation of patients with LUTS/BPH: From clinical trials to clinical practice
 F. Cruz, Porto (PT)
Alpha-blockers and benign prostatic obstruction: Still an open debate
 F. Fusco, Naples (IT)
Alpha-blockers in men with LUTS/BPH as a foundation drug
 C.G. Roehrborn, Dallas (US)
Round table
 C.G. Roehrborn, Dallas (US)
Closing remarks
 C.G. Roehrborn, Dallas (US)